Hsbc Holdings PLC Has $458,000 Stake in iTeos Therapeutics, Inc. $ITOS

Hsbc Holdings PLC lifted its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 62.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 76,993 shares of the company’s stock after buying an additional 29,587 shares during the quarter. Hsbc Holdings PLC owned about 0.20% of iTeos Therapeutics worth $458,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of ITOS. Wells Fargo & Company MN grew its position in shares of iTeos Therapeutics by 16.9% during the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock worth $128,000 after buying an additional 2,402 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of iTeos Therapeutics during the 4th quarter worth approximately $1,159,000. Barclays PLC grew its position in shares of iTeos Therapeutics by 17.4% during the 4th quarter. Barclays PLC now owns 132,894 shares of the company’s stock worth $1,022,000 after buying an additional 19,683 shares during the period. Dimensional Fund Advisors LP grew its position in shares of iTeos Therapeutics by 15.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company’s stock worth $9,293,000 after buying an additional 163,880 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of iTeos Therapeutics by 3.1% in the 4th quarter. Northern Trust Corp now owns 259,737 shares of the company’s stock worth $1,995,000 after purchasing an additional 7,881 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Stock Performance

Shares of NASDAQ:ITOS opened at $10.15 on Tuesday. The stock’s fifty day simple moving average is $10.14 and its two-hundred day simple moving average is $8.46. iTeos Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $17.63. The stock has a market cap of $448.73 million, a PE ratio of -2.17 and a beta of 1.31.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($1.51) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.39). On average, sell-side analysts forecast that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Insider Buying and Selling at iTeos Therapeutics

In other iTeos Therapeutics news, CEO Michel Detheux sold 43,883 shares of the firm’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total transaction of $439,707.66. Following the transaction, the chief executive officer directly owned 153,903 shares in the company, valued at approximately $1,542,108.06. This trade represents a 22.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Hallal sold 38,228 shares of the firm’s stock in a transaction on Friday, June 6th. The shares were sold at an average price of $10.24, for a total value of $391,454.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 277,185 shares of company stock worth $2,805,412. Company insiders own 14.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ITOS. Raymond James Financial set a $12.00 target price on iTeos Therapeutics in a report on Wednesday, May 14th. Wedbush reiterated an “outperform” rating and issued a $10.50 target price (down from $12.00) on shares of iTeos Therapeutics in a report on Monday, July 21st. JPMorgan Chase & Co. cut iTeos Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $15.00 to $8.00 in a report on Tuesday, May 13th. Leerink Partners reiterated a “market perform” rating and issued a $9.00 target price (down from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, HC Wainwright cut iTeos Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, May 14th. One research analyst has rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, iTeos Therapeutics presently has an average rating of “Hold” and an average target price of $15.50.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.